Methicillin-resistant Staphylococcus aureus (MRSA) is a clinically-important Gram-positive pathogen in both the hospital and outpatient settings. Over the past decade, the MRSA hospital market has become highly competitive due to the availability of numerous effective therapies. In the next few years, growth in this market will be further constrained by the anticipated generic entry of two key anti-MRSA agents: linezolid and daptomycin. Nevertheless, there remains commercial opportunity for new anti-MRSA agents able to address specific areas of unmet need.
This report focuses on the treatment of inpatients with MRSA infections and analyzes the hospital prescribing practices for infections due to MRSA and other clinically-important Gram-positive (GP) pathogens, such as community- and hospital-acquired MRSA, vancomycin-intermediate and -resistant S. aureus and vancomycin-resistant enterococci. Further, this study will evaluate the advantages and disadvantages of currently-available and emerging therapies to identify areas for product positioning and differentiation.